Company ProfilePremium

Celltrion Pharm, Inc.

Company Profile Analysis

Ticker: 068760.KQ주식회사 셀트리온제약

ESOMAR 23 Corporate BadgeISO Certifications Badge
Celltrion Pharm, Inc. - Company showcase

Year Founded & Workforce

1976

992 Employees

Celltrion Pharm, Inc. logo

Celltrion Pharm, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Celltrion Pharm, Inc. Overview

Celltrion Pharm is the Korean commercial and fill-finish arm of the Celltrion biosimilar group. It runs three businesses:

Chemical pharmaceuticals: A domestic prescription franchise anchored by the liver drug Godex, the hypertension drug Dilatrend, and diabetes and hypertension brands acquired from Takeda in 2020 (Nesina, Actos, Idalbi).

Biosimilars: Exclusive domestic sales of parent Celltrion's biosimilars, from legacy Remsima, Truxima and Herzuma to newer Yuflyma, Vegzelma, Steqeyma, Omlyclo, Eydenzelt, Stoboclo-Osenvelt and Avtozma.

Contract manufacturing (CMO): Mainly prefilled-syringe (PFS) fill-finish for Celltrion's subcutaneous products sold globally, including Remsima SC (US brand Zymfentra) and Yuflyma, from GMP-certified lines in Cheongju.

FY2025 revenue reached a record KRW 536.4 bn, with operating profit of KRW 56.1 bn. The company's growth and margins are increasingly driven by Celltrion-linked biosimilar distribution and CMO volumes rather than generics. That shift makes it a leveraged, but concentrated, play on its parent's subcutaneous-formulation strategy.


What the company does. Celltrion Pharm develops, manufactures and sells chemical (small-molecule) medicines in Korea. It is the exclusive Korean distributor of Celltrion, Inc.'s biosimilars. It also provides contract manufacturing services, principally aseptic filling of prefilled syringes. Third-party company descriptions (e.g., the StockHub profile derived from exchange data) list its therapeutic coverage as:

  • liver function improvers

  • anti-inflammatories and antihistamines

  • respiratory, cardiovascular and gastrointestinal drugs

  • hormone and metabolic-disease drugs

  • antibiotics and antifungals

  • nutritional and tonic products

  • immunology and oncology biologics

Customers are university and general hospitals, clinics, and community pharmacies.

Revenue model. Revenue is overwhelmingly product sales plus contract manufacturing service fees. There is no material subscription or licensing income. Based on FY2025 disclosed segment data:

Chemical products: (owned brands, in-licensed and acquired brands, generics): ~40% of revenue on the disclosed segment figure. The share is higher if undisclosed "other" revenue is chemical.

Biosimilar distribution: ~24%. Celltrion Pharm buys finished biosimilars from Celltrion and resells them in Korea. This is a distribution-margin model.

CMO / contract services: ~26%. Mostly PFS commercial production for Celltrion, plus commercial production of in-sourced products and other pharmaceutical services.

In H1 2026, biosimilar plus CMO revenue exceeded 53.8% of sales for the first time (IBK Investment & Securities initiation, September 2026). That marks the structural pivot away from generics.

Value-chain position.

Chemicals: vertically integrated. R&D of incremental modified drugs (개량신약) and combinations, API sourcing, finished-dose manufacturing at Ochang and Jincheon, and domestic sales and marketing. The company has "in-sourced" production of Takeda-origin brands (Nesina, Actos, Idalbi) that were previously imported, improving gross margin.

Biosimilars: downstream only. Domestic commercialisation (hospital drug-committee listings, tenders, medical marketing) of products developed and manufactured by Celltrion.

CMO: mid-stream. Drug product (fill-finish) manufacturing of Celltrion drug substance into prefilled syringes for global supply.

Customer types and end markets.

  • Korean tertiary and general hospitals (biosimilars, specialty chemicals)

  • Clinics and pharmacies (primary-care chemicals)

  • Celltrion, Inc. as a related-party CMO customer. IBK estimated ~88% of H1 2026 CMO revenue came from Celltrion-directed PFS production.

End markets: Korean prescription drug market (hepatology, cardiometabolic, diabetes, immunology, oncology, ophthalmology, allergy/respiratory, bone), plus global SC biologic demand indirectly via CMO.

Company's own characterisation. In its earnings releases the company describes FY2025 as a year in which top-line growth combined with cost and cost-of-goods improvements. It names three operating levers:

  1. strengthening competitiveness of core products;

  2. keeping PFS fill-finish lines at maximum utilisation;

  3. improving chemical profitability through in-sourced brands (Nesina, Actos, Idalbi).

It frames 2026 as continued "high growth" with a profitability focus. (Paraphrased from the FY2025 preliminary results release, 5 February 2026.)

Independent characterisation. Celltrion Pharm is best understood as a captive service and distribution satellite of Celltrion, Inc., with a declining-share generics base attached. Its economics are set by three things:

  • domestic biosimilar uptake, which Korean government policy increasingly favours;

  • Celltrion's global SC-formulation volumes, which drive PFS utilisation;

  • intra-group transfer pricing on both the distribution and CMO legs.

This creates genuine growth optionality, notably the announced KRW 2 trn PFS capacity plan. It also creates material related-party concentration and governance considerations. Those considerations were central to the failed 2024 merger, when parent-company shareholders argued Celltrion Pharm's market value exceeded its fundamental value.

Strategy

Stated corporate strategy (themes paraphrased from FY2024–FY2026 earnings releases and investor communications)

  1. Strengthen core-product competitiveness: Godex, Dilatrend, Remsima, Truxima.

  2. Rapid market entry of new biosimilars: data-led, indication-specific academic marketing for Steqeyma, Eydenzelt, Omlyclo and later launches.

  3. Maximise PFS line utilisation and expand CMO: capitalise on global SC formulation demand.

  4. Chemical profitability via in-sourcing: Nesina, Actos, Idalbi.

  5. Differentiated R&D: combination and incrementally modified drugs in diabetes and hypertension.

  6. Profitability-centred stable growth: the 2026 guidance framing.

Strategic initiatives in the last 24 months

Sustainability and ESG commitments: not publicly disclosed specifically for Celltrion Pharm.

Cost programmes: none announced with quantified targets. Management credits commission savings and production in-sourcing for margin gains.

Medium-term financial targets and guidance

  • No explicit quantitative revenue or margin guidance for Celltrion Pharm was found in public disclosures for 2026 or beyond. The company's guidance language is "maintain high growth" with a profitability focus.

  • A "future business/management plan" fair disclosure (장래사업ㆍ경영계획) was filed by Celltrion Pharm in mid-2026 (StockHub disclosure index).

  • Parent-level context: Celltrion targets KRW 5.3 trn revenue in 2026 (an implied KRW 1.8 trn operating profit is cited by the Korea Herald). It targets 18 biosimilars by 2030, 41 by 2038, and ~20 novel-drug candidates by 2027.

Products & Services

Pricing for Korean prescription drugs is set by the national reimbursement list (HIRA/MOHW price notification). Individual product prices are not disclosed in company releases. "Latest sales" figures are company-disclosed revenues.

Chemical Pharmaceuticals

ProductDescription / mechanismIndication / targetOrigin & timingLatest disclosed sales (KRW Bn)
Godex Capsules (고덱스캡슐)Hepatoprotective "liver solvent" combination capsule. Flagship legacy Hanseo product.Liver-function improvement (chronic liver disease, elevated liver enzymes). Hospital and clinic prescribing.Hanseo origin; acquired with Hanseo in 2009. Survived a price re-evaluation in 2023. Chong Kun Dang's FY2024 commentary references Godex among products it introduced to its own sales line-up, indicating a domestic co-promotion arrangement (terms not disclosed).FY2020 65.7; FY2023 69.1 (+11%); FY2024 66.8; FY2025 68.4 (+2.4%); Q2 2026 17.7 (+10.1%)
Dilatrend Tablets (딜라트렌정)Carvedilol (beta/alpha-1 blocker)Hypertension; cardiovascularFull-scale sales by Celltrion Pharm began in 2024.FY2024 50.2; FY2025 57.4 (+14.3%); Q2 2025 15.1
Nesina family (네시나, 네시나액트, etc.)Alogliptin (DPP-4 inhibitor) and fixed-dose combinations. Nesina Act = alogliptin + pioglitazone.Type 2 diabetesTakeda acquisition (2020); licence transfers completed Jan 2022. Production in-sourced.Nesina Act ~11.2 (2021 outpatient Rx, UBIST, pre-transfer); Nesina Q2 2025 6.4 (+65.7%)
Actos (액토스)Pioglitazone (TZD)Type 2 diabetesTakeda acquisition. In-sourced production.Q2 2025 1.8
Idalbi (이달비)Azilsartan (ARB)HypertensionTakeda acquisition. Production in-sourced (completed by 2024).FY2023 >10.0 (+14.8%); Q2 2025 2.7
Amlozet Tablets (암로젯정)Three-drug fixed combination for hypertension plus hyperlipidaemiaPatients with co-morbid hypertension and dyslipidaemiaIn-house incrementally modified drug; approved and launched Feb 2025Grouped with Nesina/Actos in Q2 2026 commentary (~8.6 combined, +4.2%)
Donerion Patch (도네리온패취)Donepezil transdermal patch, applied twice weekly (vs once-daily oral)Alzheimer's dementiaIn-house incrementally modified drug; MFDS approval ~2021–22—
Other generics portfolioBroad domestic generic range (cardiovascular, GI, CNS, anti-infectives, etc.) built after the 2015 Ochang plant openingPrimary care and hospitals70+ approvals in 2015–2017"Other generics" revenue grew from KRW 9.3 bn (2010) to KRW 115.2 bn (2024) (IB Tomato)
Global chemical productsExport chemical products, including HIV antiretroviral CT-G7International tenders / partnersCommercial ramp from Q3 2020~43 (FY2020); later years not itemised
Pipeline: combination modified drugsFY2023 disclosures: development completed for 3 hypertension products, 1 herpes zoster antiviral, 1 liver product. Primary hypercholesterolaemia plus essential hypertension combination in registration (this became Amlozet).Chronic diseaseR&D focus on diabetes and hypertension combinations—

Biosimilars (domestic exclusive distribution of Celltrion products)

ProductMolecule (reference)Indication areaKorean launch / statusLatest disclosed sales (KRW Bn) and share data
Remsima (IV)Infliximab (Remicade)Autoimmune: RA, IBD, AS, psoriasisLong-establishedFY2023 40.4 (+24.9%); Q2 2026 11.5 (+19.2%). Domestic market share 39% in Q2 2024, highest in 3 years.
Remsima SCInfliximab subcutaneousIBD, RADomestic supply from 2021–22 (passed ~75 hospital drug committees by Feb 2022)Sales not separately disclosed
TruximaRituximab (MabThera/Rituxan)Blood cancers, RAEstablishedFY2023 14.9; Q2 2026 4.3 (+20.7%). Domestic share >30% for first time in Q2 2024.
HerzumaTrastuzumab (Herceptin)HER2+ breast and gastric cancerEstablishedFY2023 14.9
YuflymaAdalimumab, high-concentration, citrate-free (Humira)AutoimmuneLaunched 2022FY2024 3.6 (+77%); Q2 2025 1.8; Q2 2026 2.4 (+28.6%)
VegzelmaBevacizumab (Avastin)OncologyLaunched 2022Q2 2025 2.0; Q2 2026 4.0 (+93.9%)
SteqeymaUstekinumab (Stelara)Psoriasis, Crohn's, UCLaunched 1 Sep 2024Q2 2026 0.4
OmlycloOmalizumab (Xolair)Allergic asthma, chronic urticariaLaunched 1 Sep 2024. Celltrion added a pen formulation globally.Q2 2026 1.2 (+206.5%)
EydenzeltAflibercept (Eylea)Ophthalmology (nAMD, DME)Launched 1 Sep 2024—
Stoboclo / OsenveltDenosumab (Prolia / Xgeva)Osteoporosis / bone metastasesLaunched 2025Included in "new products" KRW 9.7 bn (Q2 2025, with Steqeyma, Eydenzelt, Omlyclo)
AvtozmaTocilizumab (Actemra)RA, GCA, JIAKorean approval filed Feb 2024; contributing by 2026Q2 2026 0.4
Pipeline from parentCT-P55 (secukinumab / Cosentyx), Herzuma SC (CT-P6 SC; Korean filing 28 May 2026), Keytruda- and Darzalex-referencing programmesVariousParent targets 18 biosimilars by 2030 and 41 by 2038. Note: CT-P51 (pembrolizumab) European Phase 3 was terminated early and the trial application voluntarily withdrawn (2026 disclosure).—

Contract Manufacturing (CMO / 위수탁생산)

ServiceDescriptionCustomerStatusLatest disclosed revenue (KRW Bn)
PFS commercial productionAseptic fill-finish of biologics into prefilled syringes. Supports Celltrion SC products: Remsima SC / Zymfentra, Yuflyma, plus SC demand across Herzuma and Truxima referenced in FY2025 commentary.Celltrion, Inc. (~88% of H1 2026 CMO revenue per IBK)GMP: MFDS, EMA, ANVISA, US FDA, PMDA. Lines at maximum utilisation through 2025. Current capacity ~20 m syringes/year.FY2024 92.6 (+265%); Q2 2026 35.3 (+51.9%)
Commercial production of in-sourced productsManufacturing of formerly imported brands (Takeda-origin)Internal / groupOngoingIncluded in CMO total
Other pharmaceutical services (제약용역)Ancillary servicesGroup / third partiesOngoingIncluded in CMO total
Planned PFS expansion+50 m syringes/year (to 70 m total). Phase 1 ~KRW 1 trn; total programme ~KRW 2 trn.Celltrion global SC demand; external CMO ambitionsAnnounced 2 Jul 2026. Design and groundbreaking 2028; operation 2032. Site under review (Ochang/Osong/Jincheon cited in different reports).—

Financial Narrative

Basis: K-IFRS separate. All figures KRW bn unless stated.

Sources by year:

  • FY2021: preliminary results, 23 Feb 2022 (Medigate/Biospectator)

  • FY2022: derived from the FY2023 release's stated YoY changes (Dealsite, 18 Mar 2024): revenue +0.7% (+KRW 2.8 bn), operating profit −5.5% (−KRW 2.1 bn), net income −18.1% (−KRW 4.7 bn)

  • FY2023: Dealsite/Biospectator, 18 Mar 2024

  • FY2024: Dealsite/Bizwatch, 17 Mar 2025

  • FY2025: Dealsite/Medifonews, 5 Feb 2026

  • Balance sheets and cash flows: Valueline/DataHero compilation of DART statements, accessed 16 Oct 2026

Income Statement

Notes:

  • FY2022 revenue growth is derived from FY2021 398.7 and derived FY2022 386.0.

  • FY2025 D&A = PPE depreciation 20.9 + intangible amortisation 1.3 (Valueline TTM to Dec-2025).

  • EPS = net income ÷ year-end share count on Valueline's stock-dividend-adjusted series (44.42 m for 2021 to 44.55 m for 2025).

  • Cash DPS: FY2023 and FY2024 dividends were stock-only.

Revenue CAGR FY2021–FY2025: 7.7%: (derived: (536.4 / 398.7)^(1/4) − 1).

FY2022–FY2025 CAGR: 11.6%: (derived).

Quarterly run-rate (KRW bn)

Sources: Q2 2026 fair-disclosure summary (StockHub, 4 Aug 2026) for Q2 2025–Q2 2026. Q1 2025 is derived from H1 2026 cumulative figures and their stated YoY growth rates (Dailian, 4 Aug 2026): revenue 285.4 (+17.1%), OP 32.2 (+22.7%), NI 22.5 (+22.4%). The four 2025 quarters reconcile to the FY2025 totals (536.4 / 56.0 / 38.8).

H1 2026 summary: revenue KRW 285.4 bn (+17.1%), operating income KRW 32.2 bn (+22.7%), net income KRW 22.5 bn (+22.4%). Trailing-twelve-month (TTM) to June 2026: revenue KRW 578.0 bn, operating income KRW 62.0 bn, net income KRW 42.9 bn (derived from quarterly sum).

Commentary — trends, inflections and drivers

FY2021 step-change: Revenue jumped 70.7% as the Takeda-origin portfolio (Nesina, Actos, Idalbi), worth ~KRW 70 bn in 9M 2021 alone, was layered onto Godex and the biosimilar trio. The trio rose ~18% to ~KRW 51.3 bn. Global chemical shipments also contributed.

FY2022–FY2023 plateau: Revenue stalled near KRW 386–389 bn. Operating income fell from KRW 47.8 bn to KRW 36.1 bn. The company cited endemic-phase normalisation and intensifying generic competition. In FY2023 R&D expense rose 58.9% to KRW 12.7 bn as the company built a modified-combination pipeline.

FY2024 volume inflection, margin trough: Revenue +22.9%, driven by PFS commercial production (+265% to KRW 92.6 bn), Dilatrend's first full year (KRW 50.2 bn) and chemicals (+23%). Operating margin, however, fell to 7.8%. Causes cited: generic price cuts decided in 2023, labour cost from pre-staffing new production capacity, and higher R&D. Q2 2024 OP fell 36.1% YoY on a 17.5% rise in cost of sales.

FY2025 operating leverage: Revenue +12.3%, but operating income +50.7% and net income +76.4%. Drivers: biosimilar revenue +50.8% (new launches), maximum PFS utilisation, and cost-of-goods relief from in-sourced Takeda brands, plus lower commission costs.

2026 trajectory: H1 2026 OP growth (+22.7%) outpaced revenue (+17.1%). Q2 2026 delivered a record OP of KRW 19.3 bn at a 12.6% margin, driven by CMO (+53.4%). IBK forecasts FY2026 operating income growth of ~25.5%, which implies ~KRW 70 bn on the FY2025 base (derived).

Balance Sheet

Latest interim (30 June 2026):

  • Total assets KRW 779.2 bn; equity KRW 449.2 bn; total liabilities KRW 330.0 bn

  • Cash KRW 51.7 bn; short-term financial instruments KRW 72.1 bn

  • Short-term borrowings KRW 142.0 bn; no long-term bank borrowings

  • Net debt ~KRW 18.2 bn (derived)

  • Intangibles rose to KRW 60.8 bn (software and other intangibles up; 2025 intangible additions of KRW 12.7 bn TTM to Mar-2026)

  • Book value per share KRW 10,116

Commentary:

Deleveraging: The balance sheet has steadily de-levered. Net debt fell from KRW 121.0 bn (FY2023) to KRW 25.0 bn (FY2025), as long-term bank loans were fully repaid and cash plus short-term deposits rose to KRW 117.0 bn.

Short-term funding: All remaining borrowings are short-term revolving facilities (KRW 142.0 bn). Refinancing reliance is therefore concentrated in a 12-month window, though this is typical of Korean mid-cap pharma working-capital lines.

Working capital: Working capital expanded as inventories grew (KRW 69.2 bn → KRW 122.9 bn, FY2022–FY2025), reflecting new biosimilar SKUs and in-sourced manufacturing. Receivables are structurally high, which is normal for Korean hospital channels.

Capacity plan vs balance sheet: The announced KRW 2 trn PFS plan dwarfs the current asset base (KRW 779 bn) and cash (~KRW 124 bn incl. ST deposits at Jun-2026). Dailian (2 Jul 2026) highlighted this mismatch. A company official characterised the figure as a scale under review rather than a finalised project.

Cash Flow

FY2025 values are trailing-twelve-month to 31 Dec 2025 per Valueline/DART.

TTM to 30 June 2026: OCF KRW 61.9 bn; PP&E capex KRW 12.2 bn; FCF (OCF − capex) KRW 49.7 bn; cash dividends paid KRW 8.7 bn (the first FY2025 cash dividend); treasury share purchases KRW 2.2 bn. The decline in TTM OCF versus FY2025 reflects working-capital absorption: receivables +KRW 14.1 bn, inventory +KRW 12.1 bn and prepayments +KRW 9.1 bn on a TTM basis.

Ratios

Notes:

  • ROIC: NOPAT = OP × (1 − 22% effective tax rate, derived from FY2025 tax ÷ pre-tax).

  • Market data (Valueline, 15 Oct 2026, TTM basis): ROE 9.55%, P/E 37.85x, P/B 3.61x.

Ratio commentary. Returns troughed in FY2023–FY2024, with ROE around 5.7–5.8%, as revenue growth was absorbed by generic price cuts, staffing ahead of capacity, and R&D. FY2025 marks a clear inflection: ROE 9.3%, ROA 5.4%, interest cover 8.4x. That inflection is driven almost entirely by the CMO and biosimilar legs. Receivable days are improving (208 → 150) as the CMO mix, billed to Celltrion, rises. Leverage is low, and the company is effectively net-cash-neutral after short-term deposits.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

Segment (KRW Bn)FY2023FY2024FY2025

Chemical pharmaceuticals (as disclosed)

166.5204.8214.0

Biosimilars (as disclosed)

73.386.6130.6

CMO total (FY2024 derived from FY2025 +2.8%)

—135.8139.6

of which PFS commercial production

25.492.6—

Residual / not itemised (derived)

—50.652.2

Total revenue

388.8477.8536.4

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2024FY2025

Chemical revenue growth YoY

23.04.5

Biosimilar revenue growth YoY

18.250.8

CMO revenue growth YoY

—2.8

PFS commercial production growth YoY

265.0—

Chemical share of total revenue

42.939.9

Biosimilar share of total revenue

18.124.3

CMO share of total revenue

28.426.0

Revenue by Segment

Segment (KRW Bn)Q2 2025Q2 2026YoY %

Chemical

66.367.01.1

Biosimilar / Bio

32.536.612.5

CMO

32.449.753.4

of which PFS commercial production

23.235.351.9

Total

131.3153.316.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

398.7386.0388.8477.8536.4

Revenue growth YoY (%)

70.7-3.20.722.912.3

Operating income (KRW Bn)

47.838.236.137.256.1

Operating income growth YoY (%)

102.3-20.1-5.53.150.7

D&A (KRW Bn)

————22.2

EBITDA (KRW Bn, derived = OP + D&A)

————78.3

Pre-tax income (KRW Bn, derived = NI + tax)

————49.8

Income tax expense (KRW Bn)

————11.0

Net income (KRW Bn)

34.626.021.321.938.8

EPS basic (KRW, derived on adjusted shares)

779584478492871

Cash dividend per share (KRW)

——00200

Operating margin (%)

12.09.99.37.810.5

EBITDA margin (%)

————14.6

Net margin (%)

8.76.75.54.67.2

R&D expense (KRW Bn)

—8.012.7——

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue (KRW Bn)

112.4131.3138.2154.4132.1153.3

Operating income (KRW Bn)

10.715.516.113.712.919.3

Net income (KRW Bn)

7.311.111.58.98.813.7

Operating margin (%)

9.511.811.68.99.812.6

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

599.7641.6669.5759.4

Current assets (KRW Bn)

311.9364.8391.7470.6

Cash & equivalents (KRW Bn)

31.419.745.549.9

Short-term financial instruments (KRW Bn)

17.717.424.167.1

Trade receivables (KRW Bn)

185.8222.1212.9220.3

Inventories (KRW Bn)

69.2100.4101.4122.9

Property, plant & equipment (KRW Bn)

227.8216.4205.6201.6

Goodwill (KRW Bn)

32.932.932.932.9

Goodwill & intangibles total (KRW Bn)

41.339.339.243.2

Short-term borrowings (KRW Bn)

121.2136.5150.6142.0

Current portion of long-term borrowings (KRW Bn)

17.317.34.30

Long-term borrowings (KRW Bn)

21.74.300

Total borrowings (KRW Bn)

160.2158.1154.9142.0

Net debt (KRW Bn, borrowings − cash − ST financial)

111.1121.085.325.0

Current liabilities (KRW Bn)

212.0249.3247.7283.6

Total liabilities (KRW Bn)

242.9265.0272.5323.5

Shareholders' equity (KRW Bn)

356.8376.7396.9436.0

Working capital (KRW Bn, CA − CL)

99.9115.4144.2187.0

Cash Flow

MetricFY2025

Operating cash flow (KRW Bn)

86.4

Capex — PP&E (KRW Bn)

16.2

Capex — intangibles (KRW Bn)

1.8

Free cash flow (KRW Bn, OCF − PP&E capex)

70.2

Dividends paid in cash (KRW Bn)

0

Treasury share purchases (KRW Bn)

2.4

Interest expense (KRW Bn)

6.7

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE (%, NI ÷ average equity)

7.35.85.79.3

ROA (%, NI ÷ average assets)

—3.43.35.4

ROIC (%, NOPAT ÷ (equity + net debt), derived)

———9.5

Current ratio (x)

1.471.461.581.66

Debt / equity (x, borrowings ÷ equity)

0.450.420.390.33

Net debt / EBITDA (x)

———0.32

Interest coverage (x, OP ÷ interest expense)

———8.4

Asset turnover (x)

—0.630.730.75

Days sales outstanding (days, year-end receivables)

—208163150

Revenue by Region

Channel (KRW Bn)FY2023FY2024FY2025

Domestic chemical + domestic biosimilar (disclosed segments)

239.8291.4344.6

CMO, predominantly related-party to Celltrion, end-use mostly ex-Korea

—135.8139.6

Residual / not itemised (may include exports)

—50.652.2

Total revenue

388.8477.8536.4

Share Price and Market Valuation

MetricFY2022FY2023FY2024FY2025

Share price, year-end (KRW, adjusted)

59,62186,17055,60158,000

Market capitalisation, year-end (KRW Bn)

2,647.93,833.92,476.32,583.9

Price / book, year-end (x)

—10.186.245.93

Shares outstanding (m, adjusted series)

44.4944.5244.5444.55

Valuation Multiples

MultipleCelltrion PharmCelltrion, Inc. (reference)

P/E (x)

37.8

34.4 (FY2026F, Kiwoom, Jan 2026)

EV/EBITDA (x)

~19.3

21.9 (FY2026F, Kiwoom)

EV/Sales (x)

~2.8

—

P/B (x)

3.61

2.10 (FY2026F, Kiwoom)

Dividend History

Fiscal yearCash DPS (KRW)Stock dividend (shares per share)Notes

FY2023

00.05

1,972,158 new shares

FY2024

0

~0.05

~2.06 m new shares; one source prints 0.005 (discrepancy)

FY2025

2000.02

~KRW 8.7 bn cash paid in 2026; ~43.42 m eligible shares

Analyst Conclusions

Management guidance. No numeric guidance for Celltrion Pharm. Management targets continued "high growth" with a profitability focus in 2026. It plans to maximise PFS utilisation, expand new-biosimilar prescriptions and improve chemical margins via in-sourcing.

Consensus expectations. Only IBK's published forecast was identified: FY2026 OP growth of ~25.5%, implying ~KRW 70 bn on the FY2025 base (derived). The H1 2026 run-rate (OP KRW 32.2 bn, +22.7%) is consistent with this. A seasonally stronger H2 is expected, given the parent's H2-weighted tender season and Q3 2026 strength.

Bull case

  1. CMO volume leverage. PFS commercial production grew 51.9% in Q2 2026. The parent's Q3 2026 preliminary revenue rose 45.8%, and its SC products (Zymfentra, Yuflyma, Omlyclo, Steqeyma) are gaining US and EU share. High-margin fill-finish volumes should keep compounding.

  2. Domestic biosimilar breadth. The portfolio moves from 3 legacy products to 11+ (and 18 by 2030). FY2025 biosimilar revenue rose 50.8%, and Omlyclo and Vegzelma are growing 90–200% YoY.

  3. Balance-sheet capacity and re-rating potential. Net debt is ~KRW 18 bn and ROE has inflected to ~9.5%. The stock is down 37% YTD while earnings hit records, which may compress the historic premium toward fundamentals. IBK's target implies ~67% upside.

Bear case

  1. Concentration and transfer-pricing risk. ~88% of CMO revenue and all biosimilar supply depend on Celltrion. The parent's own Songdo and Yesan DP build-out could divert future fill-finish volumes.

  2. Capex overreach. A ~KRW 2 trn plan against ~KRW 124 bn of liquid assets implies heavy external funding (equity, debt or parent support) and execution risk. Benefits arrive no earlier than 2032.

  3. Structural valuation overhang. P/E of ~38x and P/B of 3.6x remain above the parent. Group-structure uncertainty persists after the 2024 merger rejection. Generic price cuts cap chemical growth (Q2 2026 chemical +1.1%).

Key catalysts and monitorables (next 12 months)

  • Q3 2026 results (~mid-Nov 2026): CMO growth sustainability and OPM vs the Q2 record of 12.6%

  • Q4 2026 / FY2026 results (~Feb 2027): confirmation of ~25% OP growth

  • Definitive PFS investment decision: site, phasing, funding structure and any parent participation

  • Any external (non-Celltrion) CMO contract announcement

  • Korean launches of Herzuma SC and CT-P55 (secukinumab); new-biosimilar prescription ramps

  • FY2026 dividend decision (Dec 2026): continuation of the cash component

  • Generic price-policy changes and reimbursement re-evaluations

  • Any signal on revisiting a Celltrion–Pharm combination (currently none; treat as speculative)

Concluding analyst verdict

Celltrion Pharm has completed a quiet but decisive transformation. It is no longer primarily a Korean generics house. As of H1 2026, more than half of revenue comes from distributing its parent's biosimilars and filling its parent's prefilled syringes. The financial consequences are now visible. FY2025 operating profit rose 50.7% to KRW 56.1 bn, Q2 2026 set a record at KRW 19.3 bn, ROE has recovered to ~9.5%, and net debt has fallen close to zero. These gains rest on durable drivers: the parent's accelerating SC franchise in the US and Europe, and a policy environment in Korea that favours biosimilar adoption.

The investment debate is not about growth, but about who captures it. Celltrion Pharm's profitability is set within a related-party system. Celltrion supplies the products, buys the CMO output, and is simultaneously building its own drug-product capacity. The 2024 merger collapse showed that parent-company shareholders view Pharm's valuation sceptically, and the market has since de-rated the stock by more than a third in 2026 even as earnings hit records. At ~38x TTM earnings and 3.6x book, the shares are no longer extreme relative to the parent. They still embed confidence that intra-group economics will remain favourable and that the ~KRW 2 trn PFS expansion will be funded and filled.

On balance, the operating trajectory is clearly positive and the near-term earnings set-up favourable: H2 seasonality plus strong parent Q3 volumes. But governance and concentration risks are structural, not cyclical. Investors should treat Celltrion Pharm as a higher-beta, lower-control proxy for Celltrion's SC strategy. It is attractive on momentum and balance-sheet strength. Its re-rating, however, depends on concrete evidence of external CMO diversification, a credible financing plan for the capacity programme, and fuller segment disclosure that reconciles revenue and reveals segment margins. Until then, a balanced-to-constructive stance, sized for event risk around group restructuring and capex decisions, appears warranted.


  • parent ownership: 54.81% vs 54.99% vs 53.81%

  • FY2024 stock dividend ratio: 0.005 vs ~0.05 implied

  • founding/establishment date: 1976 vs 2000 vs 2009

  • annual segment totals vs reported revenue

Derived figures are labelled with their method. None were estimated.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureBackgroundCompensation

Yoo Young-ho (유영호)

President & CEO

CEO since Jan 2024

Previously executive vice president (부사장) within the Celltrion group; promoted to president with the CEO appointment (Kormedi, 2 Jan 2024). Leads the PFS investment programme.

Not publicly disclosed in sources reviewed. Korean rules require disclosure only for executives paid ≥KRW 500 m.

Seo Jung-jin (서정진)

Inside director and co-chairman of the board (appointed 28 Mar 2023, 2-year term); Celltrion Group chairman

Group founder

Founder of Celltrion. Returned to boards of all listed group companies in March 2023. Re-elected at Celltrion, Inc. in March 2025.

Not disclosed for Celltrion Pharm

Seo Jung-soo (서정수)

Former CEO (2016–2023); now Celltrion vice chairman

CEO ~8 years

Inha University (accounting); ex-GS E&C executive; joined Celltrion 2012; Celltrion president 2014

—

Major Shareholders

HolderStakeSource / date

Celltrion, Inc.

54.81%–54.99%

Korea Times (Aug 2024), sell-side notes (2024–2026); Dailian (Jul 2026)

Treasury shares

~0.26 m shares (~0.6%)

Dividend notice, Dec 2025

Free float / minority investors

~44–45% (derived)

—

Competitive Landscape

Peer Comparison FY2025

Company (FY2025)Revenue (KRW Bn)Revenue growth (%)Operating margin (%)

Celltrion Pharm

536.412.310.5

Chong Kun Dang

1,692.46.74.8

Daewoong Pharmaceutical

1,570.9—12.5

Hanmi Pharmaceutical

1,547.5—16.7

Recent Developments

Celltrion Pharm's Q3 2026 results had not been released as of the research cut-off. Historically they arrive in mid-November.

Company Snapshot

$377.5M

Revenue

992

Employees

1976

Founded

Cheongju, South Korea

Headquarters

SWOT Analysis

Strengths

  • Record, accelerating profitability. FY2025 operating profit KRW 56.1 bn (+50.7%) and net income KRW 38.8 bn (+76.4%). Q2 2026 record OP of KRW 19.3 bn at a 12.6% margin.
  • Globally certified PFS capacity. Cheongju PFS lines hold GMP certification from MFDS, EMA, ANVISA, FDA and PMDA. They ran at maximum utilisation in 2025.
  • Exclusive domestic biosimilar pipeline. Biosimilar revenue +50.8% in FY2025 to KRW 130.6 bn, with 2024–2025 launches (Omlyclo, Steqeyma, Eydenzelt, Stoboclo-Osenvelt, Avtozma).
  • Durable legacy brands. Godex KRW 68.4 bn and Dilatrend KRW 57.4 bn in FY2025, together ~23% of revenue.
  • Improved balance sheet. Net debt down from KRW 121.0 bn (FY2023) to KRW 25.0 bn (FY2025); no long-term bank debt; interest cover 8.4x.
  • Strong hospital market positions. Remsima 39% and Truxima >30% domestic shares (Q2 2024).

Weaknesses

  • Customer concentration. ~88% of H1 2026 CMO revenue came from Celltrion PFS production (IBK).
  • Low R&D scale. KRW 12.7 bn in FY2023 (3.3% of revenue) vs peers with far larger budgets. FY2024–FY2025 not quantified.
  • Below-peer margins. FY2025 OPM of 10.5% vs Hanmi ~16.7% and Daewoong ~12.5%.
  • Disclosure gaps. Annual segment figures do not reconcile to total revenue (KRW ~52 bn residual in FY2025). No segment profit disclosure.
  • Working-capital intensity. Receivables of KRW 220.3 bn (DSO ~150 days) and inventory up 21% in FY2025. TTM OCF fell from KRW 86.4 bn (FY2025) to KRW 61.9 bn (Jun-2026).
  • Funding mismatch for the growth plan. Cash plus ST deposits ~KRW 124 bn (Jun-2026) vs a ~KRW 2 trn PFS programme.

Opportunities

  • PFS 3.5× capacity expansion to 70 m syringes/year, positioned for global SC demand. Phase 1 operation targeted for 2032.
  • Parent's portfolio growth: 18 biosimilars by 2030 and 41 by 2038. Each adds domestic sales and potential fill-finish volume. Herzuma SC was filed in Korea in May 2026.
  • External CMO customers: the CEO's stated objective to diversify beyond Celltrion.
  • Policy tailwind: Korean government support for biosimilar uptake (IBK).
  • Margin uplift from in-sourcing of Nesina, Actos and Idalbi production (management commentary FY2025).
  • Possible eventual group restructuring. Celltrion stated it could revisit the merger once both companies are "appropriately valued" (16 Aug 2024 notice).

Threats

  • Generic price cuts. The 2023 price-cut decision compressed 2024 operating profit; Q2 2024 OP fell 36.1% YoY.
  • Intra-group capacity substitution. Parent is building DP capacity at Songdo (>70% complete in Mar 2026) and Yesan, and DS at Branchburg.
  • Pipeline attrition at the parent. CT-P51 (pembrolizumab) European Phase 3 terminated early in 2026.
  • Governance-driven valuation discount. 70.4% of Celltrion shareholders opposed the 2024 merger, citing Pharm overvaluation. The share price is down ~37% YTD in 2026 despite record profits.
  • Competitive biosimilar entry. Samsung Bioepis (9 Korean products) and Dong-A ST (ustekinumab) erode first-mover pricing.
  • Macro and geopolitical volatility. Middle East tensions in 2026 prompted parent buybacks and weighed on Korean bio equities.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr–May 2025Q1 2025 results: record Q1 revenue. Chemical +27% (KRW 51.6 bn) and biosimilar +14% (KRW 20.8 bn) segment growth. New biosimilars visible.Confirms new-launch traction; margin expansion via commission savings and in-sourcing
2025Domestic launch and ramp of Stoboclo-Osenvelt (denosumab)Expands bone-disease franchise
14 Aug 2025Q2 2025: revenue KRW 131.3 bn (+12.1%), OP KRW 15.5 bn (+64.8%), OPM 11.8%. Biosimilar KRW 32.5 bn (+58.3%); new biosimilars KRW 9.7 bn; PFS KRW 23.2 bn (+24.6%).Record Q2; margin reset upward
Aug 2025Parent Celltrion decides to acquire a US drug-substance plant (Eli Lilly's Branchburg, NJ facility)Expands group SC/DS supply; potential long-term PFS demand driver
Nov 2025Q3 2025: revenue KRW 138.2 bn, OP KRW 16.1 bn, NI KRW 11.5 bnQ3 record for the company at that time
11 Dec 2025Board declares FY2025 dividend: KRW 200 cash plus 0.02-share stock per share. Parent recapitalises Celltrion USA by ~KRW 782.4 bn to close Branchburg.First meaningful cash payout in years
31 Dec 2025Parent announces Q4 2025 preliminary results (36.8% OPM), cites PFS-heavy new-product momentumPositive read-through for CMO demand
Jan 2026Parent begins operating the Branchburg plantGroup capacity expansion
5 Feb 2026FY2025 results: revenue KRW 536.4 bn (+12.3%), OP KRW 56.1 bn (+50.7%), NI KRW 38.8 bn (+76.4%). Godex KRW 68.4 bn, Dilatrend KRW 57.4 bn, biosimilars KRW 130.6 bn (+50.8%), CMO KRW 139.6 bn.Record year; first time above KRW 500 bn revenue
Mar 2026AGM approves FY2025 dividend. Parent cancels ~9.11 m treasury shares (~KRW 1.7 trn).Group shareholder-return context
24 Mar 2026Parent commits KRW 1.2 trn to Songdo and US capacity expansion, incl. Branchburg to 141,000 L DS. A new DP plant at Yesan (South Chungcheong) is in design.Group may internalise some DP fill capacity: both an opportunity and a competitive consideration for Pharm
Mar–Apr 2026Middle East geopolitical tensions weigh on Korean equities; parent buys back KRW 100 bn of sharesMarket backdrop
May 2026Q1 2026: revenue KRW 132.1 bn (+17.5%), OP KRW 12.9 bn (+20.6%), NI KRW 8.8 bnSeasonal Q1 softness, but YoY growth intact
21 May 2026Parent approves a 0.05 bonus issueGroup capital action
28 May 2026Parent files Korean approval for Herzuma SC (CT-P6 SC)Future domestic product and potential PFS volume
2 Jul 2026CEO Yoo announces a ~KRW 2 trn phased PFS investment (to 70 m syringes; Phase 1 ~KRW 1 trn; 2028 start, 2032 operation) at a presidential briefing in AsanLargest strategic commitment in company history; funding and site unresolved
2 Jul 2026Dailian flags the funding gap: cash ~KRW 50 bn vs a KRW 2 trn plan. Company says scope and site are undecided.Execution and funding risk signal
3 Jul 2026Parent Q2 2026 preliminary: revenue ~KRW 1.30 trn (+35.2%), OP ~KRW 430 bn (+77.3%); new products >60% of salesRead-through: SC product momentum
2026 (mid-year)Parent discloses early termination of the CT-P51 (pembrolizumab biosimilar) European Phase 3 and voluntary withdrawal of the trial planPipeline setback for a potential future domestic product
27–28 Jul 2026Parent final Q2: revenue KRW 1.394 trn, OP KRW 451.8 bn; Omlyclo >KRW 100 bn in a quarterStrong group volumes
4 Aug 2026Q2 2026: revenue KRW 153.3 bn (+16.8%), record OP KRW 19.3 bn (+24.4%), NI KRW 13.7 bn. CMO KRW 49.7 bn (+53.4%); PFS KRW 35.3 bn (+51.9%); Remsima KRW 11.5 bn; Godex KRW 17.7 bn.Record quarterly operating profit
Aug 2026Market cap ~KRW 1.85 trn at the Q2 disclosureValuation context
2 Sep 2026 (approx.)IBK initiates Celltrion Pharm: Buy, TP KRW 61,000. H1 bio+CMO share 53.8%; forecasts FY2026 OP +25.5%; ~88% of H1 CMO from Celltrion PFS.First notable sell-side initiation in the period
10 Sep 2026 (from)Korean Commercial Act amendments: cumulative voting mandatory for large listed companies (Celltrion, Inc. adopting)Governance regime tightening across the group
29 Sep 2026Parent announces CPHI Milan (6–8 Oct) participation for novel-drug and CDMO partneringGroup CDMO positioning
12 Oct 2026Parent Q3 2026 preliminary: revenue ~KRW 1.5 trn (+45.8%), OP ~KRW 510 bn (+69.2%); US shares: Steqeyma 15%, Yuflyma 11%, Truxima 39%, Inflectra 31%Strong read-through for Pharm CMO volumes in H2 2026
15 Oct 2026Celltrion Pharm closes at KRW 36,500 (market cap KRW 1.62 trn), down ~37% YTDShare price has decoupled from earnings growth

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (FY2023–FY2025): Total revenue rose from KRW 388.8 Bn in FY2023 to KRW 536.4 Bn in FY2025.
Celltrion Pharm, Inc. — Revenue by Segment (FY2023–FY2025)
Series (KRW Bn)FY2023FY2024FY2025
Total revenue388.8477.8536.4
Chemical pharmaceuticals (as disclosed)166.5204.8214
Biosimilars (as disclosed)73.386.6130.6
of which PFS commercial production25.492.6—
Residual / not itemised—50.652.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.